(CercleFinance.com) – AB Science announces that a clinical development program for masitinib in sickle cell disease is one of the 19 winning projects as part of the sixth call for projects ‘hospital-university health research’ of the AB Science Investment Program future.
In this context, the SICKMAST project will receive funding of 9.2 million euros, intended in particular for a phase II clinical trial to evaluate the effectiveness of masitinib in this very widespread genetic disease, a trial of which the AP -HP will be the promoter.
AB Science will mainly intervene through the supply of masitinib and in monitoring the pharmacovigilance data of the product. It remains free to execute as it sees fit the possible phase III which will succeed phase II in the event of success.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
